Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1124524 · FYE Dec 31 · Prices AT CLOSE 2026-08-21 (USD) Last $17.13 · Day +2.51% · Mkt cap $868M · P/E (FY) 12.2× · 1Y +101.5% · Off 52W high −0.4% · Vol (1Y) 56.3% Price2023-08-21 → 2026-08-21 CYRX close: $14.3 on 2023-08-21 to $17.1 on 2026-08-21. Split-adj closes · 240 of 5,279 · price returnⓘ At a glance | Short interest4.9% of sh out | | Days to cover4.0d | | 13F net flow (QoQ)−0.39% | | Top-10 13F concentration55.6% | | Next report (est.)2026-11-05 |
SI 2026-07-31 · 13F 2026-Q1ⓘ Key fundamentalsFY 2025 | P/E (FY)12.2× | | Sales (TTM)$186.5M | | Earnings (TTM)-$33.7M | | ROE17.3% | | Net margin44.4% | | ROIC−24.0% | | Sales growth 3Y−9.4% |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns | YTD+78.4% | | 1Y+101.5% | | 3Y+19.9% | | 5Y−71.8% | | 10Y+715.7% | | Since incept. (ann.)−16.5% |
Total return · from 2005-08-22ⓘ Risk | Ann. volatility (1Y)56.3% | | Ann. volatility (3Y)78.9% | | Sharpe (1Y)1.51 | | Sharpe (3Y)0.45 | | Max drawdown (1Y)−31.5% | | Max drawdown (3Y)−75.0% | | Beta (3Y vs SPY)2.19 |
Daily returns, ann.ⓘ Top institutional holders13F 2026-Q1 | Manager | Shares | Value | % sh out | QoQ |
|---|
| CADIAN CAPITAL MANAGEMENT, LP | 4.8M | $40M | 9.58% | −3.8% | | MORGAN STANLEY | 4.6M | $38M | 9.18% | −0.2% | | BlackRock, Inc. | 4.0M | $33M | 7.98% | −0.4% | | MILLENNIUM MANAGEMENT LLC | 3.0M | $25M | 5.96% | −8.5% | | VANGUARD CAPITAL MANAGEMENT LLC | 2.1M | $18M | 4.25% | new | | FRED ALGER MANAGEMENT, LLC | 1.7M | $14M | 3.41% | −3.1% | | Assenagon Asset Management S.A. | 1.5M | $12M | 3.00% | +0.6% | | MAK CAPITAL ONE LLC | 1.4M | $12M | 2.85% | +18.7% |
Δ vs 2025-Q4ⓘ Latest reported quarterslast report 2026-08-06 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2026-06-30 | 2026-08-06 | −$0.20 | −109.4% | $49.0M | +7.7% | | 2026-03-31 | 2026-05-04 | −$0.25 | — | $47.8M | +16.5% | | 2025-12-31 | 2026-03-03 | −$0.27 | — | $45.5M | +9.6% | | 2025-09-30 | 2025-11-04 | −$0.18 | — | $44.2M | +15.4% |
As-reported XBRL · next 2026-11-05 est.ⓘ Segment mixFY2025 (ended Dec 2025) Life Sciences Services 57% · Life Sciences Products 43% business · TAGGED revenueⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
| 
